A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

NCT02773368 · Completed

Last updated 2026-05-28

This clinical trial compares two diabetes treatments, IDegLira and IGlar, added to SGLT2i therapy, in adults with type 2 diabetes to see how well they control blood sugar levels.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 420 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-05 · est. completion 2017-10

Where 88 sites · Argentina, Canada, Finland, Hungary, India, Russia, Slovakia, Slovenia, Spain, Switzerland, United States

What this study is testing ClinicalTrials.gov NCT02773368 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.

Treatments tested

insulin degludec/liraglutide Drug

IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
insulin glargine Drug

IGlar will be given subcutaneously ( s.c., under the skin) once daily.

Main thing measured	Change in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02773368 ↗